Plant extract compositions with synergistic hypoglycemic activity and their applications
By optimizing the mass ratio of mulberry leaf extract, white kidney bean extract, and bitter melon powder, a plant extract composition with synergistic hypoglycemic activity was formed, which solved the problem of limited hypoglycemic effect in the existing technology and achieved significant hypoglycemic effect and improvement of peripheral nerve inflammation.
Patent Information
- Application Number
- CN202511618262.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-09
- Publication Date
- 2026-11-10
AI Technical Summary
Existing dietary adjustments and chemical hypoglycemic drugs have limitations in treating hyperglycemia-related metabolic diseases, such as poor adherence, long-term side effects, and significant individual differences. Natural plant active extracts have the advantages of multi-target and low toxicity in regulating glucose metabolism, but the hypoglycemic effect of existing plant extract combinations is limited.
By optimizing the mass ratio of mulberry leaf extract, white kidney bean extract, and bitter melon powder to 8:(1~24):(1~64), a plant extract composition with synergistic hypoglycemic activity was formed. Utilizing the synergistic effect of 1-deoxynojirimycin in mulberry leaf extract, α-amylase inhibitor in white kidney bean extract, and total saponins in bitter melon powder, a composition with significantly enhanced hypoglycemic effect was prepared.
It significantly improves the blood glucose lowering effect, alleviates peripheral nerve inflammation, synergistically enhances peripheral nerve fluorescence intensity, inhibits the enzyme activity of bacterial dipeptidyl peptidase-4 in vitro, and provides a more stable and better-compliant blood glucose lowering solution.
Smart Images

Figure CN123059104A_ABST
Abstract
Description
Technical Field
[0001] This application is a divisional application of application number 2025105928753, filed on May 9, 2025, entitled "Plant Extract Composition with Synergistic Hypoglycemic Activity and Its Application". This invention relates to the field of plant extract technology, and more particularly to a plant extract composition with synergistic hypoglycemic activity and its application. Background Technology
[0002] Metabolic diseases are a group of illnesses caused by disorders of metabolic processes, involving impairments in the synthesis, breakdown, transformation, or transport of substances in the body. Among these, hyperglycemia-related metabolic diseases have received considerable attention. Currently, methods for the prevention and treatment of hyperglycemia-related metabolic diseases include adopting a low-sugar, low-fat, and high-fiber diet, as well as taking hypoglycemic drugs.
[0003] However, relying solely on traditional dietary adjustments and chemical hypoglycemic drugs often has limitations such as poor adherence, long-term side effects, and significant individual variability. In recent years, an increasing number of studies have shown that active extracts derived from natural plants (such as polyphenols, flavonoids, saponins, terpenes, and alkaloids) offer advantages in regulating glucose metabolism, improving insulin sensitivity, inhibiting gluconeogenesis, and reducing oxidative stress and chronic inflammation, exhibiting multi-target and low-toxicity benefits. For example, plant-based active substances such as puerarin and momordicin have been widely used in functional foods and traditional Chinese medicine preparations, and their hypoglycemic effects and safety have been verified in clinical trials. These findings indicate that plant extracts, as an important component of food, health products, and even drugs, are becoming a key strategy for preventing and intervening in hyperglycemia-related metabolic diseases, demonstrating unique application value in the prevention, adjunctive treatment, and even disease management of these diseases. Summary of the Invention
[0004] This invention provides a plant extract composition with synergistic hypoglycemic activity and its application. It uses mulberry leaf extract, white kidney bean extract and bitter melon powder as raw materials to provide effective active ingredients for lowering blood sugar. When used in a specific ratio, it can significantly enhance the hypoglycemic effect and has no toxic side effects.
[0005] Specifically, this invention, through the rational compounding of other plant extracts with hypoglycemic or related regulatory effects, found that when the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder is 8:(1~24):(1~64), the hypoglycemic effect of the resulting composition is significantly better than other compounding ratios. This has very important technical significance for preparing hypoglycemic foods or medicines with better efficacy, more comprehensive effects, more stability and better compliance.
[0006] In a first aspect, the present invention provides a plant extract composition comprising mulberry leaf extract, white kidney bean extract and bitter melon powder in a mass ratio of 8:(1~24):(1~64).
[0007] According to the plant extract composition provided by the present invention, preferably, the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder is 8:(1~8):(1~22).
[0008] According to the plant extract composition provided by the present invention, preferably, the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder is 8:(1~3):(1~18).
[0009] According to the plant extract composition provided by the present invention, preferably, the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder is 8:(1~3):(1~8).
[0010] According to the plant extract composition provided by the present invention, preferably, the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder is 8:3:(1~8).
[0011] According to the plant extract composition provided by the present invention, preferably, the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder is 8:(1~3):(3~4).
[0012] According to the plant extract composition provided by the present invention, preferably, the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder is 8:3:(3~8).
[0013] 1-Deoxynojirimycin (1-DNJ) is a polyhydroxypiperidine alkaloid found in mulberry trees. It has a structure similar to α-1,4-glucose and is an α-glucosidase inhibitor. It has hypoglycemic, antitumor and antiviral activities and is also an indicator component of mulberry leaf extract.
[0014] Phaseolin, a component of white kidney bean extract, is a natural α-amylase inhibitor. Chemically, it is a glycoprotein that effectively inhibits starch breakdown, allowing it to be excreted through the gastrointestinal tract. Furthermore, due to its large molecular weight, phaseolin does not enter the bloodstream or act on the central nervous system, thus it does not suppress appetite during weight loss. Even at high doses, it has no side effects and exhibits good safety. This invention uses α-amylase inhibitor activity as an indicator component of white kidney bean extract.
[0015] Saponins in bitter melon are a class of glycosides whose aglycones are triterpenoids or steroidal compounds, composed of sugars and aglycones. They can not only lower blood sugar levels by regulating the uptake of glucose by the body's cells, but also alleviate inflammation through various pathways. The bioactive components of bitter melon include saponins, proteins, polysaccharides, polyphenols, and sterols. This invention uses total saponins as the indicator component of bitter melon powder.
[0016] According to the plant extract composition provided by the present invention, the mulberry leaf extract contains 1-deoxynojirimycin at a content greater than or equal to 1.0 g / 100 g; Alternatively, the α-amylase inhibitor activity of the white kidney bean extract is greater than or equal to 1 × 10⁻⁶. 5 U / g; Alternatively, the total saponin content of the bitter melon powder is greater than or equal to 1.5% w / w.
[0017] According to the plant extract composition provided by the present invention, the mulberry leaf extract contains 1-deoxynojirimycin at a content greater than or equal to 1.0 g / 100 g, and the white kidney bean extract contains α-amylase inhibitor activity greater than or equal to 1 × 10⁻⁶. 5 The total saponin content of the bitter melon powder is greater than or equal to 1.5% w / g.
[0018] This invention, through extensive experiments, has found that using mulberry leaf extract with a 1-deoxynojirimycin content greater than or equal to 1.0 g / 100 g and α-amylase inhibitor activity greater than or equal to 1×10⁻⁶ is effective. 5 White kidney bean extract with a U / g concentration and bitter melon powder with a total saponin content of ≥1.5% w / w play a key role in ensuring the hypoglycemic, peripheral nerve inflammation improvement, and peripheral nerve damage effects of the above-mentioned plant extract composition.
[0019] According to the plant extract composition provided by the present invention, the mulberry leaf extract is obtained by water extraction; the white kidney bean extract is obtained by water extraction; and the bitter melon powder is obtained by water extraction.
[0020] Secondly, the present invention also provides a method for preparing the plant extract composition as described above. This plant extract composition can be prepared by any suitable physical mixing method, including the step of mixing mulberry leaf extract, white kidney bean extract, and bitter melon powder. The order of mixing the mulberry leaf extract, white kidney bean extract, and bitter melon powder is not particularly specified, as long as the three are mixed evenly. The final mixture has a mass ratio of mulberry leaf extract, white kidney bean extract, and bitter melon powder of 8:(1~24):(1~64).
[0021] Thirdly, the present invention also provides a plant extract composition for lowering blood sugar, comprising the plant extract composition as described above, or the plant extract composition prepared by the method described above, wherein the active ingredient for lowering blood sugar is derived from the mulberry leaf extract, the white kidney bean extract, and the bitter melon powder.
[0022] Fourthly, the present invention also provides the use of the plant extract compositions described above in maintaining healthy blood glucose levels in subjects, improving diabetic complications, slowing the progression of diabetes, and treating or preventing hyperglycemia-related metabolic diseases.
[0023] The application includes administering the plant extract composition to a subject in an effective amount. The subject may be a human being. The effective dosage range can be 500~12000mg / day, for example 500mg / day, 550mg / day, 600mg / day, 650mg / day, 700mg / day, 750mg / day, 800mg / day, 850mg / day, 900mg / day, 950mg / day, 1g / day, 1.5g / day, 2g / day, 2.5g / day, 3g / day, 3.5g / day, 4g / day, 4.5g / day, 5g / day, 5.5g / day, 6g / day, 6.5g / day, 7g / day, 7.5g / day, 8g / day, 8.5g / day, 9g / day, 9.5g / day, 10g / day, 10.5g / day, 11g / day, 11.5g / day, or 12g / day.
[0024] Fifthly, the present invention also provides the use of the plant extract composition for lowering blood sugar as described above in the preparation of foods for maintaining healthy blood sugar levels, improving diabetic complications, or slowing the progression of diabetes.
[0025] In a sixth aspect, the present invention also provides a food composition comprising the plant extract composition for lowering blood sugar as described above; the food composition is used to maintain healthy blood sugar levels, improve diabetic complications, or slow the progression of diabetes.
[0026] According to the food composition provided by the present invention, the food composition is an oral liquid, tea, lozenge, capsule, beverage or effervescent tablet.
[0027] The food composition of the present invention can also be a functional health product suitable for subjects.
[0028] The subject may be a mammal, preferably a human. Administration may be administered orally, via the gastrointestinal tract, by injection, spray, or through physical or chemical means.
[0029] In a seventh aspect, the present invention also provides the use of the plant extract composition for lowering blood sugar as described above in the preparation of a medicament for treating and / or preventing hyperglycemia-related metabolic diseases.
[0030] According to the application provided by the present invention, the hyperglycemia-related metabolic disease is selected from one or more of diabetes mellitus, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, diabetic gangrene, diabetic cachexia, diabetic dyslipidemia, diabetic coronary heart disease, diabetic cerebrovascular disease, and diabetic peripheral vascular disease.
[0031] In an eighth aspect, the present invention also provides a pharmaceutical composition comprising the plant extract composition for lowering blood sugar as described above; said pharmaceutical composition is used to treat and / or prevent hyperglycemia-related metabolic diseases.
[0032] According to the pharmaceutical composition provided by the present invention, the pharmaceutical composition is an injection, tablet, powder, granule, pill, capsule, oral liquid, ointment, cream or spray.
[0033] The pharmaceutical composition provided according to the present invention further comprises pharmaceutically acceptable excipients.
[0034] According to the pharmaceutical composition provided by the present invention, the excipients are selected from one or more combinations of pharmaceutically acceptable diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption enhancers, surfactants, adsorbents, lubricants, and sustained-release agents.
[0035] Dipeptidyl peptidase-4 (DPP-4) is a serine protease that rapidly cleaves and inactivates incretins such as GLP-1 and GIP. The application of DPP-4 inhibitors can inhibit the degradation of GLP-1 and GIP, enhance the activity of incretins and neuropeptides, reduce fasting and postprandial glucose concentrations and glycated hemoglobin levels, and improve insulin sensitivity and β-cell function. As an important intestinal bacterial host isoenzyme, bacterial dipeptidyl peptidase-4 can hydrolyze GLP-1 and significantly affect the occurrence and development of metabolic-related diseases, making it a novel target for combating metabolic diseases. This invention reveals that the aforementioned plant extracts possess certain technical effects in inhibiting the enzymatic activity of bacterial dipeptidyl peptidase-4 and can be used as inhibitors of bacterial dipeptidyl peptidase-4.
[0036] In a ninth aspect, the present invention also provides an in vitro method for inhibiting the enzymatic activity of bacterial dipeptidyl peptidase-4, comprising the step of contacting bacterial dipeptidyl peptidase-4 or cells containing bacterial dipeptidyl peptidase-4 with the plant extract composition described above.
[0037] In a tenth aspect, the present invention also provides the use of a plant extract composition in vitro for non-therapeutic purposes as a bacterial dipeptidyl peptidase-4 inhibitor.
[0038] The present invention provides a plant extract composition with synergistic hypoglycemic activity and its application. By optimizing the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder to 8:(1~24):(1~64), the plant extract with mulberry leaf extract, white kidney bean extract and bitter melon powder as the main raw materials has a significantly better hypoglycemic effect than the plant extracts in the prior art and other compound plant extract compositions.
[0039] Meanwhile, the above-mentioned plant extract composition also has the effect of synergistically reducing the number of neutrophils around nerves and improving peripheral nerve inflammation, synergistically enhancing the fluorescence intensity of peripheral nerves and improving peripheral nerve damage, and inhibiting the enzyme activity of bacterial dipeptidyl peptidase-4 in vitro. Attached Figure Description
[0040] To more clearly illustrate the technical solutions in this invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.
[0041] Figure 1 This is a test result diagram of Test Example 3 provided by the present invention.
[0042] Figure 2 This is a test result diagram of Test Example 4 provided by the present invention. Detailed Implementation
[0043] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions of this invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some, not all, of the embodiments of this invention. All other embodiments obtained by those skilled in the art based on the embodiments of this invention without creative effort are within the scope of protection of this invention.
[0044] In some specific embodiments of the present invention, a plant extract composition is first provided, comprising mulberry leaf extract, white kidney bean extract and bitter melon powder in a mass ratio of 8:(1~24):(1~64).
[0045] Taking the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder in this invention as 8:(1~24):(1~64) as an example, this expression can be understood as: the mass ratio of mulberry leaf extract and white kidney bean extract satisfies 8:(1~24), and the mass ratio of mulberry leaf extract and bitter melon powder satisfies 8:(1~64).
[0046] In some specific embodiments of the present invention, when the mulberry leaf extract is 8 parts by weight, the number of parts of white kidney bean extract can be any value or a range of any values among 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 parts.
[0047] In some specific embodiments of the present invention, when the mulberry leaf extract is 8 parts by weight, the number of parts of bitter melon powder can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 parts. Any value or a range of any values from 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, and 64.
[0048] In some specific embodiments of the present invention, the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder is 8:(1~8):(1~22).
[0049] In some specific embodiments of the present invention, the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder is 8:(1~3):(1~18).
[0050] In some specific embodiments of the present invention, the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder is 8:(1~3):(1~8).
[0051] According to the plant extract composition provided by the present invention, preferably, the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder is 8:3:(1~8).
[0052] In some specific embodiments of the present invention, the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder is 8:(1~3):(3~4).
[0053] According to the plant extract composition provided by the present invention, preferably, the mass ratio of mulberry leaf extract, white kidney bean extract and bitter melon powder is 8:3:(3~8).
[0054] In some specific embodiments of the present invention, the plant extract composition comprises, by weight, 1-9 parts of white kidney bean extract, 1-18 parts of mulberry leaf extract, and 1-18 parts of bitter melon powder.
[0055] Specifically, in some embodiments of the present invention, the number of parts of white kidney bean extract can be any value or a range of any values among 1, 2, 3, 4, 5, 6, 7, 8, and 9. The number of parts of mulberry leaf extract can be any value or a range of any values among 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18. The number of parts of bitter melon powder can be any value or a range of any values among 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18.
[0056] In some specific embodiments of the present invention, the 1-deoxynojirimycin content of the mulberry leaf extract is greater than or equal to 1.0 g / 100 g; Alternatively, the α-amylase inhibitor activity of the white kidney bean extract is greater than or equal to 1 × 10⁻⁶. 5 U / g; Alternatively, the total saponin content of the bitter melon powder is greater than or equal to 1.5% w / w.
[0057] In some specific embodiments of the present invention, the 1-deoxynojirimycin content of the mulberry leaf extract is greater than or equal to 1.0 g / 100 g, and the α-amylase inhibitor activity of the white kidney bean extract is greater than or equal to 1 × 10⁻⁶. 5 The total saponin content of the bitter melon powder is greater than or equal to 1.5% w / g.
[0058] In some specific embodiments of the present invention, the mulberry leaf extract is obtained by water extraction; the white kidney bean extract is obtained by water extraction; and the bitter melon powder is obtained by water extraction.
[0059] In some specific embodiments of the present invention, a method for preparing the plant extract composition as described above is also provided, comprising the step of mixing mulberry leaf extract, white kidney bean extract, and bitter melon powder. The mass ratio of mulberry leaf extract, white kidney bean extract, and bitter melon powder in the resulting mixture is 8:(1~24):(1~64).
[0060] In some specific embodiments of the present invention, a plant extract composition for lowering blood sugar is also provided, comprising the plant extract composition as described above, or the plant extract composition prepared by the method described above, wherein the active ingredients for lowering blood sugar are derived from mulberry leaf extract, white kidney bean extract and bitter melon powder.
[0061] In some specific embodiments of the present invention, the use of the plant extract compositions described above in maintaining healthy blood glucose levels in subjects, improving diabetic complications, slowing the progression of diabetes, and treating or preventing hyperglycemia-related metabolic diseases is also provided.
[0062] The application includes administering the plant extract composition to a subject in an effective amount. The subject may be a human being. The effective dosage range can be 500~12000mg / day, for example 500mg / day, 550mg / day, 600mg / day, 650mg / day, 700mg / day, 750mg / day, 800mg / day, 850mg / day, 900mg / day, 950mg / day, 1g / day, 1.5g / day, 2g / day, 2.5g / day, 3g / day, 3.5g / day, 4g / day, 4.5g / day, 5g / day, 5.5g / day, 6g / day, 6.5g / day, 7g / day, 7.5g / day, 8g / day, 8.5g / day, 9g / day, 9.5g / day, 10g / day, 10.5g / day, 11g / day, 11.5g / day, or 12g / day.
[0063] In some specific embodiments of the present invention, the use of the plant extract composition for lowering blood sugar as described above in the preparation of foods for maintaining healthy blood sugar levels, improving diabetic complications, or slowing the progression of diabetes is also provided.
[0064] In some specific embodiments of the present invention, a food composition is also provided, comprising the plant extract composition for lowering blood sugar as described above; the food composition is used to maintain healthy blood sugar levels, improve diabetic complications, or slow the progression of diabetes.
[0065] In some specific embodiments of the present invention, the food composition is an oral liquid, tea, lozenge, capsule, beverage, or effervescent tablet.
[0066] The food composition of the present invention can also be a functional health product suitable for subjects.
[0067] The subject may be a mammal, preferably a human. Administration may be administered orally, via the gastrointestinal tract, by injection, spray, or through physical or chemical means.
[0068] In some specific embodiments of the present invention, the use of the plant extract composition for lowering blood sugar as described above in the preparation of a medicament for treating and / or preventing hyperglycemia-related metabolic diseases is also provided.
[0069] In some specific embodiments of the present invention, the hyperglycemia-related metabolic disease is selected from one or more of diabetes mellitus, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, diabetic gangrene, diabetic cachexia, diabetic dyslipidemia, diabetic coronary heart disease, diabetic cerebrovascular disease, and diabetic peripheral vascular disease.
[0070] In some specific embodiments of the present invention, a pharmaceutical composition is also provided, comprising the plant extract composition for lowering blood sugar as described above; the pharmaceutical composition is used to treat and / or prevent hyperglycemia-related metabolic diseases.
[0071] In some specific embodiments of the present invention, the pharmaceutical composition is an injection, tablet, powder, granule, pill, capsule, oral liquid, ointment, cream, or spray.
[0072] In some specific embodiments of the present invention, the pharmaceutical composition further comprises pharmaceutically acceptable excipients.
[0073] In some specific embodiments of the present invention, the excipients are selected from one or more combinations of pharmaceutically acceptable diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorbent carriers, lubricants, and sustained-release agents.
[0074] In some specific embodiments of the present invention, an in vitro method for inhibiting the enzymatic activity of bacterial dipeptidyl peptidase-4 is also provided, comprising the step of contacting bacterial dipeptidyl peptidase-4 or cells containing bacterial dipeptidyl peptidase-4 with the plant extract composition described above. The cells may be bacterial cells expressing bacterial dipeptidyl peptidase-4. Bacterial dipeptidyl peptidase-4 may contain the amino acid sequence of SEQ ID NO: 1.
[0075] In some specific embodiments of the present invention, the use of a plant extract composition in vitro as a non-therapeutic inhibitor of bacterial dipeptidyl peptidase-4 is also provided.
[0076] The following section presents some specific implementation examples, and... Figures 1-2 This invention describes plant extract compositions with synergistic hypoglycemic activity and their applications.
[0077] Unless otherwise specified in the following embodiments, the techniques or conditions described in the literature in this field, or the product instructions, shall be followed. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased through legitimate channels. The source information for some raw materials is as follows: Sample, solvent standard dilution water.
[0078] Metformin hydrochloride tablets (hereinafter referred to as metformin): white tablets, batch number ACR8818, manufactured by Sino-American Shanghai Squibb Co., Ltd., with ultrapure water as the solvent.
[0079] Sitagliptin phosphate tablets (hereinafter referred to as sitagliptin): yellow tablets, batch number Y008396, Hangzhou Merck Pharmaceutical Co., Ltd., solvent is ultrapure water.
[0080] Cyclocarya paliurus extract: prepared by water extraction, with total flavonoids of 2.01 g / kg and total saponins of 1.0 g / 100 g.
[0081] Wheat bran extract, batch number XT20250118, Xi'an Boao Xintian Plant Development Co., Ltd.
[0082] Pancreatic oligopeptides: Batch number 20241108820, Dezhou Lanli Biotechnology Co., Ltd.
[0083] Egg yolk powder: Batch number 20230203, Zhejiang Aige Biotechnology Co., Ltd.
[0084] D-(+)-glucose: Batch number A2425167, Shanghai Aladdin Biochemical Technology Co., Ltd.
[0085] Anhydrous ethanol: Batch number 20240123, Sinopharm Chemical Reagent Co., Ltd.
[0086] Methylcellulose: Batch number J16IS217502, Shanghai Yuanye Biotechnology Co., Ltd.
[0087] Preparation Example 1: White Kidney Bean Extract This preparation example provides a method for preparing white kidney bean extract, the process of which is as follows: The powdered or granular substance is made from white kidney beans through raw material screening, crushing, water extraction, sterilization, and spray drying. The α-amylase inhibitor activity of the obtained product is greater than or equal to 5 × 10⁻⁶. 4 U / g.
[0088] Following the method of this preparation example, white kidney bean extracts with the following different properties were obtained by changing the material-to-liquid ratio conditions of water extraction: White kidney bean extract 1: α-amylase inhibitor activity ≥ 3 × 10⁻⁶ 5 U / g.
[0089] White kidney bean extract 2: α-amylase inhibitor activity ≥ 1 × 10⁻⁶ 5 U / g.
[0090] White kidney bean extract 3: α-amylase inhibitor activity ≥ 1 × 10⁻⁶ 4 U / g.
[0091] Preparation Example 2: Mulberry Leaf Extract This preparation example provides a method for preparing mulberry leaf extract, the process of which is as follows: It is produced from mulberry leaves through processes such as water extraction, microfiltration, ultrafiltration, concentration, spray drying, and packaging. The mulberry leaf extract contains mulberry leaf alkaloid ≥ 0.2g / 100g and 1-deoxynojirimycin content ≥ 0.8g / 100g.
[0092] Following the method of this preparation example, mulberry leaf extracts with the following different properties were obtained by changing the material-to-liquid ratio conditions of water extraction: Mulberry leaf extract 1:1-deoxynojirimycin (1-DNJ) 1.1g / 100g.
[0093] Mulberry leaf extract 2:1-DNJ 1.0g / 100g.
[0094] Mulberry leaf extract 3:1-DNJ 0.8g / 100g.
[0095] Preparation Example 3: Bitter Melon Powder This preparation example provides a method for preparing bitter melon powder, the process of which is as follows: The solid is made from bitter melon through water extraction, filtration, concentration, drying, pulverization, sieving, inspection and packaging. The total saponin content (calculated as ginsenoside Re) of the obtained solid is greater than or equal to 0.5% w / w.
[0096] Following the method of this preparation example, bitter melon powder with the following different properties was obtained by changing the material-to-liquid ratio conditions of water extraction: Bitter melon powder 1: Total saponin content (calculated as ginsenoside Re) is greater than or equal to 1.5% w / w.
[0097] Bitter melon powder 2: Total saponin content (calculated as ginsenoside Re) is greater than or equal to 0.5% w / w.
[0098] Laboratory animals: Zebrafish were raised in aquarium water at 28℃ (water quality: 200mg of instant sea salt added per 1L of reverse osmosis water, conductivity 450~550μS / cm; pH 6.5~8.5; hardness 50~100mg / L CaCO3), provided by the aquarium breeding center of Hangzhou Huante Company. The laboratory animal use license number is: SYXK (Zhejiang) 2022-0004. The husbandry and management met the requirements of international AAALAC certification (certification number: 001458), and the IACUC ethics review number is: IACUC-2025-11865-01.
[0099] Equipment and consumables information: Dissecting microscope: SZX7, OLYMPUS, Japan.
[0100] CCD camera: VertA1, Shanghai Tusen Vision Technology Co., Ltd.
[0101] Precision electronic balance: CP214, OHAUS, USA.
[0102] Ultrasonic cleaning machine: JP-010T, Shenzhen Jiemeng Cleaning Equipment Co., Ltd.
[0103] Fully Automatic Rapid Sample Grinding Instrument: JXFSTPRP-24L, Shanghai Jingxin Laboratory Equipment Technology Department.
[0104] High-speed refrigerated centrifuge: Heraeus Fresco 17, ThermoFisher, Germany.
[0105] Tabletop large-capacity low-speed centrifuge: TD5A, Changsha Yingtai Instrument Co., Ltd.
[0106] Motorized focusing continuous zoom fluorescence microscope: AZ100, Nikon, Japan.
[0107] Blood glucose meter: ACCU-CHEK Performa, Roche Diagnostics Products (Shanghai) Co., Ltd.
[0108] Blood glucose meter test strips: Batch number 478829, Roche Diagnostics Products (Shanghai) Co., Ltd.
[0109] Examples 1-8 and Comparative Examples 1-7 A plant extract composition is obtained by fully mixing mulberry leaf extract 1, white kidney bean extract 1 and bitter melon powder 1 as raw materials. The weight parts of each component are shown in Table 1 below.
[0110] Table 1 Example 9 It is basically the same as Example 2, except that the same mass of white kidney bean extract 1 is replaced with white kidney bean extract 2.
[0111] Example 10 It is basically the same as Example 2, except that the same mass of mulberry leaf extract 1 is replaced with mulberry leaf extract 2.
[0112] Example 11 It is basically the same as Example 2, except that the same amount of bitter melon powder 1 is replaced with bitter melon powder 2.
[0113] Comparative Example 8 It is basically the same as Example 2, except that the same mass of white kidney bean extract 1 is replaced with white kidney bean extract 3.
[0114] Comparative Example 9 It is basically the same as Example 2, except that the same mass of mulberry leaf extract 1 is replaced with mulberry leaf extract 3.
[0115] Comparative Example 10 A plant extract composition is obtained by thoroughly mixing the ingredients listed in Table 2 below, with the weight parts of each ingredient shown in Table 2 below.
[0116] Table 2
[0117] Comparative Example 11 A plant extract composition is obtained by thoroughly mixing the ingredients listed in Table 3 below, with the weight parts of each ingredient shown in Table 3 below.
[0118] Table 3
[0119] Comparative Example 12 A plant extract composition is obtained by thoroughly mixing the ingredients listed in Table 4 below, with the weight parts of each ingredient shown in Table 4 below.
[0120] Table 4
[0121] Test Example 1: Hypoglycemic Effect of Single Component Plant Extracts on Zebrafish Test Method: Wild-type AB strain zebrafish (5 dpf) were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (experimental group). Test samples (obtained by dissolving plant extracts in water, concentrations shown in Table 1) were administered. Metformin was used as the positive control at a concentration of 400 μg / mL. Normal and model control groups were also established. Each beaker contained 25 mL. Except for the normal control group, the other experimental groups were given 1.5 mg / mL egg yolk powder in water during the day and 30 mg / mL glucose in water at night to establish a high-glucose, high-fat zebrafish model. After treatment at 28℃ for 2 days, the zebrafish were washed three times with standard dilution water. Data were collected using a blood glucose meter, and the glucose levels of the zebrafish were analyzed. The statistical analysis results of this index were used to evaluate the auxiliary hypoglycemic effect of the test samples. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software; p < 0.05 indicated statistical significance.
[0122] Table 5 In the table, compared with the model control group, * indicates p<0.05, ** indicates p<0.01, and *** indicates p<0.001.
[0123] Test Example 2: Hypoglycemic Effect of Plant Extract Composition on Zebrafish Test method: Basically the same as Test Example 1, except that: in addition to the test sample in Test Example 1, the test samples also included the plant extract compositions of Examples 1-11 and Comparative Examples 1-12, and the total concentration of plant extracts in the test samples containing plant extracts was 125 μg / mL. The test results are shown in Table 6. Among them, the drug in the positive control group was metformin, the plant extract in control group 1 was bitter melon powder 1, the plant extract in control group 2 was mulberry leaf extract 1, and the plant extract in control group 3 was white kidney bean extract 1.
[0124] Table 6 The data in the table above show that the positive control group, controls 1-3, examples 1-11, and comparative examples 1-12 all exhibited auxiliary hypoglycemic effects. At a concentration of 125 μg / mL, examples 1-11 showed significantly better auxiliary hypoglycemic effects than controls 1-3. However, the auxiliary hypoglycemic effects of comparative examples 1-12 were not significantly different from those of controls 1-3. This indicates that, under the same raw material composition and experimental concentration conditions, the hypoglycemic effects of the compositions in examples 1-11 are not only significantly better than those of single-component plant extracts, but also significantly higher than those of the other compositions.
[0125] Test Example 3: Effect of Plant Extract Composition on the Number of Perineural Neutrophils in Zebrafish Test Methods: Transgenic green fluorescent zebrafish (MPX (myeloperoxidase)) with 5 days post-fertilization (dpf) were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (experimental group). The test sample (concentration 125 μg / mL, see Table 7 for experimental groups) was administered in aqueous solution. Sitagliptin (concentration 350 μg / mL) was used as the positive control. A normal control group and a model control group were also set up, with each beaker containing 25 mL. Except for the normal control group, the other experimental groups were administered 1.5 mg / mL egg yolk powder in aqueous solution during the day and 30 mg / mL glucose in aqueous solution at night to establish a high-glucose, high-fat zebrafish model. After treatment at 28℃ for 2 days, 10 zebrafish from each experimental group were randomly selected and photographed under a fluorescence microscope. Data were analyzed and collected using NIS-ElementsD 3.20 advanced image processing software. The number of neutrophils around nerves was analyzed, and the statistical analysis results of this index were used to evaluate the auxiliary hypoglycemic effect of the sample. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software, and p < 0.05 indicated statistical significance. Among the control groups, the plant extract in control group 4 was bitter melon powder (1g), the plant extract in control group 6 was mulberry leaf extract (1g), and the plant extract in control group 6 was white kidney bean extract (1g). The test results are as follows... Figure 1 As shown in Table 7 below, Figure 1 In this context, the normal group corresponds to the normal control group, the model group corresponds to the model control group, sitagliptin corresponds to the positive control group, monomer control group 1 corresponds to control group 4, monomer control group 2 corresponds to control group 5, monomer control group 3 corresponds to control group 6, and compositions 1 to 8 correspond to Examples 1 to 8 in sequence.
[0126] Table 7 The data in the table above show that, compared to the model control group, controls 4-6, examples 1-8, and comparative examples 1-7 all exhibited auxiliary hypoglycemic effects, specifically by reducing the number of neutrophils around nerves and improving peripheral nerve inflammation. Among these, at a concentration of 125 μg / mL, the intervention groups of examples 1-7 showed significantly better efficacy in reducing peripheral nerve inflammation than controls 4-6 and comparative examples 1-7. This indicates that, under the same raw material composition and experimental concentration conditions, appropriately proportioned white kidney bean extract, mulberry leaf extract, and bitter melon powder have a synergistic effect in reducing the number of neutrophils around nerves and improving peripheral nerve inflammation.
[0127] Test Example 4: Effect of Plant Extract Composition on the Number of Perineural Neutrophils in Zebrafish Test Methods: 5-day-fly transgenic peripheral nerve green fluorescent zebrafish (Hb9) were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (experimental group). Samples were administered in water (concentration 125 μg / mL, see Table 8 for experimental groups). Sitagliptin was used as the positive control at a concentration of 350 μg / mL. Normal control and model control groups were also set up. Each beaker had a volume of 25 mL. Except for the normal control group, the other experimental groups were administered 1.5 mg / mL egg yolk powder in water during the day and 30 mg / mL glucose in water at night to establish a high-glucose, high-fat zebrafish model. After treatment at 28℃ for 2 days, 10 zebrafish from each experimental group were randomly selected and photographed under a fluorescence microscope. Data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software. The fluorescence intensity of the peripheral nerves was analyzed, and the statistical analysis results of this index were used to evaluate the auxiliary hypoglycemic effect of the samples. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software, and p < 0.05 indicated statistical significance. Among the control groups, control group 7 contained 1 part bitter melon powder, control group 8 contained 1 part mulberry leaf extract, and control group 9 contained 1 part white kidney bean extract. The test results are as follows... Figure 2 As shown in Table 8 below, Figure 2 In this study, sitagliptin corresponds to the positive control group, monomer control group 1 corresponds to control group 7, monomer control group 2 corresponds to control group 8, monomer control group 3 corresponds to control group 9, and compositions 1 to 8 correspond to Examples 1 to 8 in sequence.
[0128] Table 8 The data in the table above show that, compared to the model control group, control groups 7-9, examples 1-8, and comparative examples 1-7 all exhibited auxiliary hypoglycemic effects, specifically by enhancing peripheral nerve fluorescence intensity and improving peripheral nerve damage. Among these, at a concentration of 125 μg / mL, the intervention groups of examples 1, 2, 3, 4, 6, and 7 showed significantly better auxiliary enhancement of peripheral nerve damage than control groups 7-9 and comparative examples 1-7. This indicates that, under the same raw material composition and experimental concentration conditions, appropriately proportioned white kidney bean extract, mulberry leaf extract, and bitter melon powder have a synergistic effect in enhancing peripheral nerve fluorescence intensity and improving peripheral nerve damage.
[0129] Test Example 5: In vitro assay to inhibit bacterial dipeptidyl peptidase-4 activity Test method: (1) The DPP4 gene was cloned into the pET22b vector, and a 6×His tag was added to the C-terminus. The resulting plasmid was then transformed into Escherichia coli BL21(DE3). The bacteria were grown at 37°C until the OD600 reached 1.0-1.2, and the expression of the recombinant protein was induced at 18°C with 0.2 mmol / L isopropyl-β-D-thiogalactopyranoside (IPTG). After overnight induction, the bacteria were harvested and lysed by sonication. The protein was purified by Ni2+ affinity resin (Ni-NTA, Qiagen) in a buffer containing 20 mmol / L Tris-HCl (pH 8.0) and 200 mmol / L NaCl. The amino acid sequence of the bacterial DPP4 protein (SEQ ID NO: 1) is as follows: The bacterial DPP4 encoding gene can be obtained by expression and purification in E. coli or synthesized by a commercial gene synthesis company.
[0130] (2) Accurately weigh 1 part mulberry leaf extract, 1 part white kidney bean extract, 1 part bitter melon powder, and the aforementioned Examples 1-8, Comparative Examples 1-7, and Comparative Example 10. Prepare 0.1 mg / mL and 5 mg / mL solutions of the above monomers and compositions with DMSO for activity testing. Using the method in the DPP-4 inhibitor screening kit (Sigma, #MAK203), replace the human DPP4 protein with bacterial DPP4 protein (obtained in step (1)) and test the above samples. The calculation method of dipeptidyl peptidase-4 inhibitory activity (%) is as follows: Inhibition rate (%) = (control well activity - sample well activity) / control well activity × 100%. Statistical analysis of the experimental data was performed, and the inhibitory activity of each sample at this concentration was calculated as shown in Table 9. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software, and p < 0.05 indicated that the difference was statistically significant. Among them, the plant extract in control group 10 was bitter melon powder 1, the plant extract in control group 11 was mulberry leaf extract 1, and the plant extract in control group 12 was white kidney bean extract 1.
[0131] Table 9
[0132] As can be seen from the data in the table above, compared with the control group, Examples 1, 2, 4, 5, 6 and 7 showed synergistic effects at a concentration of 0.1 mg / ml. The in vitro bacterial DPP4 inhibitory activity of the composition was higher than that of the monomer. Compared with Comparative Example 10, the in vitro bacterial DPP4 inhibitory activity of Examples 2 and 4 did not show significant differences from Comparative Example 10.
[0133] At a concentration of 5 mg / ml, Examples 2, 4, and 5 exhibited a synergistic effect, with the in vitro bacterial DPP4 inhibitory activity of the compositions being higher than that of the monomers; compared with Comparative Example 10, Examples 2 and 4 were more effective.
[0134] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A plant extract composition for lowering blood sugar, characterized in that, It includes mulberry leaf extract, white kidney bean extract and bitter melon powder; the mass ratio of mulberry leaf extract to bitter melon powder is 8:(3~8), and the mass ratio of mulberry leaf extract to white kidney bean extract is 8:(1~8).
2. The plant extract composition for lowering blood sugar according to claim 1, characterized in that, The mass ratio of the mulberry leaf extract to the white kidney bean extract is 8:
3.
3. The plant extract composition for lowering blood sugar according to claim 1 or 2, characterized in that, The 1-deoxynojirimycin content of the mulberry leaf extract is greater than or equal to 1.0 g / 100 g; The α-amylase inhibitor activity of the white kidney bean extract is greater than or equal to 1×10⁻⁶. 5 U / g; The total saponin content of the bitter melon powder is greater than or equal to 1.5% w / w.
4. The plant extract composition for lowering blood sugar according to any one of claims 1 to 3, characterized in that, The mulberry leaf extract was prepared by water extraction. The white kidney bean extract was prepared by water extraction. The bitter melon powder was obtained by water extraction.
5. A method for preparing the plant extract composition for lowering blood sugar according to any one of claims 1 to 4, characterized in that, It is prepared by mixing mulberry leaf extract, white kidney bean extract and bitter melon powder as the main raw materials.
6. The use of the plant extract composition for lowering blood sugar according to any one of claims 1 to 4 in the preparation of food for maintaining healthy blood sugar levels, reducing the number of neutrophils around nerves, improving peripheral nerve inflammation, enhancing peripheral nerve fluorescence intensity, and improving peripheral nerve damage.
7. A food composition, characterized in that, The food composition includes the plant extract composition for lowering blood sugar as described in any one of claims 1 to 4; the food composition is used to maintain healthy blood sugar levels, reduce the number of neutrophils around nerves, improve peripheral nerve inflammation, enhance peripheral nerve fluorescence intensity, and improve peripheral nerve damage; Preferably, the food composition is an oral liquid, tea, lozenge, capsule, beverage, or effervescent tablet.
8. The use of the plant extract composition for lowering blood sugar according to any one of claims 1 to 4 in the preparation of a medicament for treating and / or preventing hyperglycemia-related metabolic diseases; wherein the treatment and / or prevention of hyperglycemia-related metabolic diseases is to reduce the number of neutrophils around nerves, improve peripheral nerve inflammation, enhance peripheral nerve fluorescence intensity, and improve peripheral nerve injury.
9. A pharmaceutical composition, characterized in that, The pharmaceutical composition includes the plant extract composition for lowering blood sugar as described in any one of claims 1 to 4; the pharmaceutical composition is used to treat and / or prevent hyperglycemia-related metabolic diseases; the treatment and / or prevention of hyperglycemia-related metabolic diseases includes reducing the number of neutrophils around nerves, improving peripheral nerve inflammation, enhancing peripheral nerve fluorescence intensity, and improving peripheral nerve injury; Preferably, the pharmaceutical composition is an injection, tablet, powder, granule, pill, capsule, oral liquid, ointment, cream, or spray.
10. A bacterial dipeptidyl peptidase-4 inhibitor, characterized in that, Includes the plant extract composition for lowering blood sugar as described in any one of claims 1 to 4.
